

Notice of Allowability	Application No.	Applicant(s)
	10/813,426	ALCARAZ ET AL.
	Examiner Jason M. Nolan, Ph.D.	Art Unit 1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 5/23/06.
2. The allowed claim(s) is/are 1-4, 6, 10-13 and 21-32.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. 10/149,549.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

DETAILED ACTION

Claims 1-4, 6, 10-13, and 20-32 are currently pending in the instant application, of which, **Claims 23-32** are new. **Claims 5, 7-9, and 14-19** have been cancelled.

Response to Amendment

Applicants' amendments dated May 23, 2006, in which **Claims 23-32** have been added and **Claims 5, 7-9, and 14-19** have been cancelled, are acknowledged and have been entered. The Double Patenting Rejection to **Claims 1-4, 6, 10 and 12** is withdrawn in concordance with Applicants' submission of a Terminal Disclaimer. Applicants' request for rejoinder of **Claims 11, 13, and 20-22** is acknowledged and the Claims have been considered.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Donald Bird on June 9, 2006

The application has been amended as follows:


1. Delete Claim 20.

Reasons for Allowance

The present invention pertains to the adamantane compounds of formula I in **Claim 1** and methods of using these compounds for the treatment of rheumatoid arthritis and pulmonary disease. Besides the work of the Applicants', the compounds according to formula I are free of the prior art; nothing known in the art anticipates or renders the compounds of the instant application obvious. A terminal disclaimer has been submitted in light of Applicants' 6,881,754 Patent. One skilled in the art would be enabled to make and use the compounds taught herein for the purpose of treating rheumatoid arthritis and pulmonary disease using the teachings of the Specification (assays on pages 89-90 demonstrate antagonist activity of P2X₇ receptor) in conjunction with the teachings in the prior art (described on pages 1 and 17 in the Specification and in the IDS).


Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jason M. Nolan, Ph.D.** whose telephone number is **(571) 272-4356** and electronic mail is Jason.Nolan@uspto.gov. The examiner can normally be reached on Mon - Fri (9:00 - 5:30PM). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph M^cKane** can be reached on **(571) 272-0699**. The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Jason M. Nolan, Ph.D.
Examiner
Art Unit 1626

AMAL A. SAEED, PH.D.
PRIMARY EXAMINER



Amal A. Saeed

Joseph K. M^cKane
Supervisory Patent Examiner
Art Unit 1626
Date: June 13, 2006